SG11201706273QA - Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents

Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them

Info

Publication number
SG11201706273QA
SG11201706273QA SG11201706273QA SG11201706273QA SG11201706273QA SG 11201706273Q A SG11201706273Q A SG 11201706273QA SG 11201706273Q A SG11201706273Q A SG 11201706273QA SG 11201706273Q A SG11201706273Q A SG 11201706273QA SG 11201706273Q A SG11201706273Q A SG 11201706273QA
Authority
SG
Singapore
Prior art keywords
complexes
preparation
pharmaceutical compositions
compositions containing
abiraterone acetate
Prior art date
Application number
SG11201706273QA
Other languages
English (en)
Inventor
Réka Angi
Tamás Jordán
Orsolya Basa-Dénes
Tamás Solymosi
Zsolt Ötvös
Hristos Glavinas
Genovéva Filipcsei
Original Assignee
Druggability Tech Ip Holdco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Druggability Tech Ip Holdco Ltd filed Critical Druggability Tech Ip Holdco Ltd
Publication of SG11201706273QA publication Critical patent/SG11201706273QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201706273QA 2015-02-09 2016-02-09 Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them SG11201706273QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1500055A HUP1500055A1 (hu) 2015-02-09 2015-02-09 Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
PCT/IB2016/050672 WO2016128891A1 (en) 2015-02-09 2016-02-09 Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
SG11201706273QA true SG11201706273QA (en) 2017-08-30

Family

ID=89991732

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706273QA SG11201706273QA (en) 2015-02-09 2016-02-09 Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them

Country Status (18)

Country Link
US (4) US9623034B2 (zh)
EP (1) EP3256108B1 (zh)
JP (1) JP6697473B2 (zh)
CN (1) CN107278152A (zh)
AR (1) AR103653A1 (zh)
AU (1) AU2016217534A1 (zh)
BR (1) BR112017017089A2 (zh)
CA (1) CA2976053A1 (zh)
ES (1) ES2737955T3 (zh)
HK (1) HK1246189B (zh)
HU (2) HUP1500055A1 (zh)
IL (1) IL253793B (zh)
MX (1) MX2017010280A (zh)
PL (1) PL3256108T3 (zh)
RU (1) RU2017129740A (zh)
SG (1) SG11201706273QA (zh)
TW (1) TWI696463B (zh)
WO (1) WO2016128891A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2018111991A1 (en) * 2016-12-14 2018-06-21 Druggability Technologies Ip Holdco Limited Pharmaceutical composition containing celecoxib
JP2020502144A (ja) * 2016-12-19 2020-01-23 ドラッガビリティー テクノロジーズ アイピー ホールディング カンパニー リミテッドＤｒｕｇｇａｂｉｌｉｔｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｐ Ｈｏｌｄｃｏ Ｌｉｍｉｔｅｄ スボレキサントの医薬製剤
AU2018316248A1 (en) * 2017-08-09 2020-01-30 Nangenex Nanotechnology Incorporated Pharmaceutical composition comprising Abiraterone acetate and Darulotamide
CN111617258A (zh) * 2019-02-28 2020-09-04 江苏恒瑞医药股份有限公司 一种制备阿比特龙或其衍生物药物组合物的方法及其应用
CZ2019168A3 (cs) 2019-03-20 2020-09-30 Zentiva, K.S. Farmaceutická kompozice obsahující abirateron acetát
CN110170058B (zh) * 2019-06-24 2022-02-11 李建恒 一种阿比特龙包合物及其制备方法
CN116785301A (zh) 2019-09-26 2023-09-22 湖南慧泽生物医药科技有限公司 含醋酸阿比特龙的药物组合物及其制备方法和应用
CN117881411A (zh) * 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
EP4197541A1 (en) 2021-12-15 2023-06-21 Hunan Huize Biopharma S&T Co., Ltd Abiraterone acetate-containing composition and application thereof
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
DE69417248T2 (de) 1993-10-27 1999-08-19 Merrell Pharma Inc Delta 16 ungesättigtes c17 heterocyclische steroide zur verwendung als steroid c17-20 lyase inhibitoren
US5688977A (en) 1996-02-29 1997-11-18 Napro Biotherapeutics, Inc. Method for docetaxel synthesis
ATE550022T1 (de) 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
WO2007150030A2 (en) * 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US9278134B2 (en) 2008-12-29 2016-03-08 The Board Of Trustees Of The University Of Alabama Dual functioning ionic liquids and salts thereof
CN101768199B (zh) 2009-12-24 2014-03-26 深圳万乐药业有限公司 醋酸阿比特龙的多晶型物及其制备方法
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
CN102558275A (zh) 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
ES2823805T3 (es) * 2011-04-15 2021-05-10 Janssen Pharmaceutica Nv Nanosuspensiones de fármacos secadas por congelamiento
CN102321142A (zh) 2011-09-29 2012-01-18 重庆医药工业研究院有限责任公司 一种醋酸阿比特龙晶型及其制备方法
CN102336801B (zh) 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
US9662807B2 (en) * 2011-12-21 2017-05-30 GKN Aerospace Services Structures, Corp. Method for forming a fabric preform for a composite material by separately tensioning tows
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014083512A1 (en) 2012-11-28 2014-06-05 Dr. Reddy's Laboratories Limited Process for preparation of abiraterone acetate
RU2015128794A (ru) 2012-12-20 2017-01-25 КАШИВ ФАРМА, ЭлЭлСи Композиция перорально распадающейся таблетки, обеспечивающая повышенную биодоступность
WO2014102833A2 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Process for abiraterone acetate
CA2907415C (en) 2013-03-15 2022-04-05 Iceutica Inc. Abiraterone acetate formulation
EP2813212A1 (en) * 2013-06-10 2014-12-17 Zentiva, a.s. Drug formulation using API in nanofibers
HUP1500055A1 (hu) 2015-02-09 2016-08-29 Druggability Technologies Ip Holdco Ltd Abirateron acetát komplexei, eljárás elõállításukra, és az azokat tartalmazó gyógyászati készítmények

Also Published As

Publication number Publication date
IL253793A0 (en) 2017-09-28
CA2976053A1 (en) 2016-08-18
TWI696463B (zh) 2020-06-21
CN107278152A (zh) 2017-10-20
MX2017010280A (es) 2017-12-04
JP6697473B2 (ja) 2020-05-20
RU2017129740A3 (zh) 2019-08-06
AR103653A1 (es) 2017-05-24
HK1246189B (zh) 2020-03-27
ES2737955T3 (es) 2020-01-17
US20160331763A1 (en) 2016-11-17
EP3256108B1 (en) 2019-05-01
EP3256108A1 (en) 2017-12-20
US10668016B2 (en) 2020-06-02
PL3256108T3 (pl) 2019-12-31
JP2018504443A (ja) 2018-02-15
HUP1500055A1 (hu) 2016-08-29
US20170182172A1 (en) 2017-06-29
AU2016217534A1 (en) 2017-09-07
WO2016128891A1 (en) 2016-08-18
RU2017129740A (ru) 2019-03-11
US9592244B2 (en) 2017-03-14
US10130582B2 (en) 2018-11-20
US20190046437A1 (en) 2019-02-14
BR112017017089A2 (pt) 2018-06-26
IL253793B (en) 2021-02-28
US20160228455A1 (en) 2016-08-11
US9623034B2 (en) 2017-04-18
HUE045398T2 (hu) 2019-12-30
TW201639580A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
HK1246189B (zh) 醋酸阿比特龍複合物、其製備方法及包含它們的藥物組合物
HK1254657A1 (zh) 新的羥基酯衍生物、其製備方法以及含有它們的藥物組合物
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
IL260040A (en) Complexes of celecoxib and its salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
HUP1300646A2 (en) Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1300647A2 (hu) Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
IL258977B (en) Pyperidyl derivatives, their preparation and pharmaceutical compositions containing them
SI3250188T1 (sl) Farmacevtski sestavek, ki obsega aprepitant in postopek za njegovo pripravo
EP3270912A4 (en) Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use
ZA201906202B (en) Tetrahydrate of h3 ligand, its process of preparation and pharmaceutical compositions comprising the same
HK1244283B (zh) 新的磷雜環己烷和氮磷雜環己烷衍生物、其製備方法及含有這些衍生物的藥物組合物
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
IL262489A (en) Complexes of ivacaptor and its salts and their history, a process for their preparation and pharmaceutical preparations containing them
HUP1400084A2 (hu) Dabigatran és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
PL3061765T3 (pl) Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek
HUP1300648A2 (hu) Dabigatran és származékainak komplexei,elõállításuk és gyógyszerészeti kompozícióik